{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:18:57Z","timestamp":1777706337619,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc., Lexington, MA, USA."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The EMPOWER Study (NCT03845400) was a phase 4, observational, non-interventional, multicenter study evaluating the real-world effectiveness and safety of lanadelumab in patients with hereditary angioedema (HAE). This subanalysis focused on lanadelumab effectiveness and safety in patients from Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Enrollment included patients with HAE due to C1 inhibitor deficiency. Patients were categorized as \u201cnewly treated\u201d or \u201cestablished on lanadelumab\u201d if they had received fewer than four or at least four doses before enrollment, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients from Canada were enrolled: seven newly treated and six established on lanadelumab; these patients received lanadelumab for a mean (standard deviation [SD]) duration of 315 (224) and 536 (366) days, respectively, during the study. In newly treated patients, the mean (SD) observed HAE attack rate decreased after lanadelumab initiation from 1.5 (2.9) to 0.3 (0.6) attacks per month. In patients established on lanadelumab, the mean (SD) observed HAE attack rate was 0.1 (0.1) attacks per month throughout the study. Most HAE attacks were mild or moderate in severity (newly treated, 94%; established on lanadelumab, 100%). No study discontinuations were attributed to treatment-emergent adverse events. All treatment-emergent adverse events were non-severe, non-serious, and unrelated to lanadelumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lanadelumab lowered the HAE attack rate among newly treated Canadian patients and maintained a low attack rate among those previously established on lanadelumab, demonstrating robust effectiveness across both patient groups. Effectiveness, tolerability, and safety of lanadelumab were consistent with the overall population from the EMPOWER Study, supporting the use of lanadelumab as a first-line long-term prophylactic treatment for patients with HAE in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT03845400, registered February 19, 2019.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-025-01007-9","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:04:25Z","timestamp":1768986265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct03845400","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stephen D.","family":"Betschel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Chapdelaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul K.","family":"Keith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"El-Zoeiby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Khutoryansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel N.","family":"Castaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"1","key":"1007_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1865-1380-5-39","volume":"5","author":"JA Bernstein","year":"2012","unstructured":"Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. 2012;5(1):39.","journal-title":"Int J Emerg Med"},{"issue":"14 Suppl","key":"1007_CR2","first-page":"S292","volume":"24","author":"JA Bernstein","year":"2018","unstructured":"Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24(14 Suppl):S292\u20138.","journal-title":"Am J Manag Care"},{"issue":"7","key":"1007_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"6","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.anai.2023.08.012","volume":"131","author":"SC Christiansen","year":"2023","unstructured":"Christiansen SC, Wilmot J, Castaldo AJ, Zuraw BL. The US hereditary angioedema association scientific registry: hereditary angioedema demographics, disease severity, and comorbidities. Ann Allergy Asthma Immunol. 2023;131(6):766-74.e8.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1007_CR5","unstructured":"Statistics Canada. Canada\u2019s population estimates, third quarter 2024. https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/241217\/dq241217c-eng.htm?HPA=1%26indid=4098-1%26indgeo=0. Accessed 5 Feb 2025."},{"key":"1007_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-016-0176-3","volume":"13","author":"NL Jindal","year":"2017","unstructured":"Jindal NL, Harniman E, Prior N, Perez-Fernandez E, Caballero T, Betschel S. Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36. Allergy Asthma Clin Immunol. 2017;13:4.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"1007_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-025-00953-8","volume":"21","author":"PK Keith","year":"2025","unstructured":"Keith PK, Lacuesta G, Goodyear D, Betschel SD, Yap B, Dansereau M-F, et al. Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study. Allergy Asthma Clin Immunol. 2025;21(1):13.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"1007_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.anai.2021.01.002","volume":"126","author":"EY Lee","year":"2021","unstructured":"Lee EY, Hsieh J, Borici-Mazi R, Caballero T, Kanani A, Lacuesta G, et al. Quality of life in patients with hereditary angioedema in Canada. Ann Allergy Asthma Immunol. 2021;126(4):394-400.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1007_CR9","volume":"15","author":"S Betschel","year":"2019","unstructured":"Betschel S, Badiou J, Binkley K, Borici-Mazi R, H\u00e9bert J, Kanani A, et al. The international\/Canadian hereditary angioedema guideline. Ann Allergy Asthma Immunol. 2019;15(1):72.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"34","key":"1007_CR10","doi-asserted-by":"publisher","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","volume":"289","author":"JA Kenniston","year":"2014","unstructured":"Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289(34):23596\u2013608.","journal-title":"J Biol Chem"},{"issue":"4","key":"1007_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","volume":"113","author":"Y Chyung","year":"2014","unstructured":"Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113(4):460-6.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1007_CR12","unstructured":"Takeda Canada Inc. TAKHZYRO\u00ae (lanadelumab injection). Product monograph. https:\/\/assets-dam.takeda.com\/raw\/upload\/v1662721805\/legacy-dotcom\/siteassets\/en-ca\/home\/what-we-do\/our-medicines\/product-monographs\/takhzyro\/takhzyro-pm-en.pdf. Accessed 28 Apr 2025."},{"key":"1007_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03226-3","author":"JA Bernstein","year":"2025","unstructured":"Bernstein JA, Betschel SD, Busse PJ, Banerji A, Wedner HJ, Manning M, et al. Sustained effectiveness, tolerability, and safety of long-term prophylaxis with lanadelumab in hereditary angioedema: the prospective, phase 4, noninterventional EMPOWER real-world study. Adv Ther. 2025;42:3882-901. https:\/\/doi.org\/10.1007\/s12325-025-03226-3","journal-title":"Adv Ther"},{"issue":"3","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","volume":"77","author":"A Banerji","year":"2022","unstructured":"Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77(3):979\u201390.","journal-title":"Allergy"},{"issue":"20","key":"1007_CR15","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108\u201321.","journal-title":"JAMA"},{"issue":"2","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaip.2024.12.008","volume":"13","author":"M Magerl","year":"2024","unstructured":"Magerl M, Bouillet L, Martinez-Saguer I, Gavini F, Bent-Ennakhil N, Sayegh L, et al. Real-world effectiveness of lanadelumab in hereditary angioedema: multicountry INTEGRATED observational study. J Allergy Clin Immunol Pract. 2024;13(2):378-87.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1007_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00579-6","volume":"17","author":"A Iaboni","year":"2021","unstructured":"Iaboni A, Kanani A, Lacuesta G, Song C, Kan M, Betschel SD. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada. Allergy Asthma Clin Immunol. 2021;17(1):78.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"1007_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/cea.13974","volume":"51","author":"DT Johnston","year":"2021","unstructured":"Johnston DT, Busse PJ, Riedl MA, Maurer M, Anderson J, Nurse C, et al. Effectiveness of lanadelumab for preventing hereditary angioedema attacks: subgroup analyses from the HELP study. Clin Exp Allergy. 2021;51(10):1391\u20135.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1007_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.anai.2023.03.028","volume":"131","author":"WR Lumry","year":"2023","unstructured":"Lumry WR, Maurer M, Weller K, Riedl MA, Watt M, Yu M, et al. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2023;131(1):101\u20138. e3","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-025-01007-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-01007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-01007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:44:20Z","timestamp":1774284260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-025-01007-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/s13223-025-01007-9","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This protocol was approved by the ethics committees of the participating sites. The study was performed according to the ethical principles of the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice Guidelines, and the requirements of the public registration of clinical trials. Written informed consent was obtained prior to participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SDB has been a speaker and\/or received advisor fees from Astria Therapeutics, BioCryst, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharvaris, and Takeda; and received research funding from CSL Behring and Takeda. HC has been a speaker and\/or received advisor fees from Alexion, CSL Behring, Novartis, Pharming, and Takeda; and received research funding within the last 2\u00a0years (Principal Investigator) from Alexion, CSL Behring, GSK, KalVista Pharmaceuticals, Merck, Novartis, Pharvaris, Sanofi, Sobi, and Takeda. RG reports site research at ALK-Abell\u00f3, AstraZeneca, DBV Technologies, GSK, Moderna, Novartis, Regeneron, and Sanofi; consultancy for ALK-Abell\u00f3, Bausch+Lomb, Regeneron, and Sanofi-Genzyme; and has received speaker fees from Bausch+Lomb and Novartis. MDG has been a speaker and\/or received advisor fees from Alexion, BioCryst, CSL Behring, Medison, Pfizer, Sanofi, Sobi, and Takeda; and has received research funding from Takeda. PKK has received research funding\/honoraria from CSL Behring and Takeda; and advisory board\/speaker fees from ALK-Abell\u00f3, AstraZeneca, Bausch+Lomb, BioCryst, CSL Behring, GSK, Medexus Pharmaceuticals, Novartis, Sanofi, Takeda, and Valeo Pharma. AE-Z is an employee of Takeda Canada, Inc., and holds stock\/options in Takeda Pharmaceutical Company Limited. NK is an employee of Cytel, contracted by Takeda Development Center Americas, Inc. DNE is an employee of Takeda Development Center Americas, Inc., and holds stock and\/or share options in Takeda Pharmaceutical Company Limited.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}